Pfizer Inc vs Yum! Brands, Inc. — how do they compare? Pfizer Inc trades at $27.88 (market cap $158.39B), while Yum! Brands, Inc. trades at $144.94 (market cap $40.80B). The key difference: Pfizer Inc is far larger — about 3.9× Yum! Brands, Inc.'s market cap, and Pfizer Inc pays the higher dividend (6.19%). Which is the better fit depends on your goals.
| PFE | YUM | |
|---|---|---|
Market Cap | $158.39B | $40.80B |
Volume | 29,869,932 | — |
Sector | Health | Consumer Cyclical |
52-Week High | $29.02 | $168.16 |
52-Week Low | $23.60 | $138.21 |
Enterprise Value | $209.89B | $52.40B |
Dividend Yield | 6.19% | 2.01% |
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $27.78, down 2.36% today, with a consensus price target of $28.33 suggesting modest upside. The stock shows mixed technical signals with bullish moving averages but neutral oscillators. Recent earnings have consistently beaten expectations, though revenue declined from pandemic peaks. The company maintains strong cash flow generation and a solid dividend yield of approximately 3.1%.
Pfizer presents a value opportunity with reasonable valuation metrics and dividend stability, but faces headwinds from post-COVID revenue normalization and patent expirations. The company's pipeline progress in obesity and oncology could drive future growth, though execution risks remain. Analyst sentiment leans cautious with 59% hold ratings.
YUM trades at $149.59, down 0.74% on the day, with a bearish technical signal and neutral oscillators. The company reported revenue of $8.21B and net income of $1.56B in 2025, with a P/E ratio of 18.83. Recent developments include the sale of Pizza Hut for approximately $1.5B to LongRange Capital, with proceeds aimed at debt reduction and share buybacks, alongside a declared $0.75 quarterly dividend.
The outlook is mixed: analyst consensus is a buy with a $173.60 price target, but high debt and a legal investigation pose risks. Earnings have beaten expectations in two of the last three quarters, with Q3 2026 results pending. The stock offers potential upside from strategic refocusing and buybacks, balanced against consumer spending pressures and leverage concerns.
Trailing returns across standard periods
Latest headlines on both assets
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →Yum Brands is a U.S.-based restaurant operator featuring a portfolio of four brands: KFC (26,930 global units), Pizza Hut (18,380 units), Taco Bell (7,790 units), and The Habit Burger (310 units) at year-end 2021. With $58 billion in 2021 systemwide sales, the firm is the second-largest restaurant company in the world, behind McDonald's ($112.5 billion) but ahead of Restaurant Brands International ($36 billion) and Starbucks ($25 billion). Yum is 98% franchised, with the largest franchisee, Yum China, created via a 2016 spinoff transaction (after which Yum China agreed to pay 3% royalties to Yum Brands in perpetuity). Yum is the newest evolution of Tricon Brands, formerly a division of PepsiCo, and generates the bulk of its revenue from franchise royalties and marketing contributions.
Read more on YUM →